Misoprostol for induction of labour to terminate pregnancy in the second or third trimester for women with a fetal anomaly or after intrauterine fetal death.
BACKGROUND
A woman may need to give birth prior to the spontaneous onset of labour in situations where the fetus has died in utero (also called a stillbirth), or for the termination of pregnancy where the fetus, if born alive would not survive or would have a permanent handicap. Misoprostol is a prostaglandin medication that can be used to induce labour in these situations.


OBJECTIVE
To compare the benefits and harms of misoprostol to induce labour to terminate pregnancy in the second and third trimester for women with a fetal anomaly or after intrauterine fetal death when compared with other methods of induction of labour.


METHODS
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (November 2009).


METHODS
Randomised controlled trials comparing misoprostol with placebo or no treatment, or any other method of induction of labour, for women undergoing induction of labour to terminate pregnancy in the second and third trimester following an intrauterine fetal death or for fetal anomalies.


METHODS
Both authors independently assessed trial quality and extracted data.


RESULTS
We included 38 studies (3679 women).Nine studies included pregnancies after intrauterine deaths, five studies included termination of pregnancies because of fetal anomalies when the fetus was still alive and the rest (24) presented the pooled data for intrauterine deaths, fetal anomalies and social reasons.When compared with agents that have traditionally been used to induce labour in this setting (for example, gemeprost, prostaglandin E(2) and prostaglandin F(2alpha)), vaginal misoprostol is as effective in ensuring vaginal birth within 24 hours, with a similar induction to birth interval. Vaginal misoprostol is associated with a reduction in the occurrence of maternal gastrointestinal side effects such as nausea, vomiting and diarrhoea when compared with other prostaglandin preparations. While the different treatments involving various prostaglandin preparations appear comparable for the reported outcomes, the information available regarding rare maternal complications, such as uterine rupture, is limited.


CONCLUSIONS
The use of vaginal misoprostol in the termination of second and third trimester of pregnancy is as effective as other prostaglandin preparations (including cervagem, prostaglandin E(2) and prostaglandin F(2alpha)), and more effective than oral administration of misoprostol. However, important information regarding maternal safety, and in particular the occurrence of rare outcomes such as uterine rupture, remains limited. Future research efforts should be directed towards determining the optimal dose and frequency of administration, with particular attention to standardised reporting of all relevant outcomes and assessment of rare adverse events. Further information is required about the use of sublingual misoprostol in this setting.
Dodd
Jodie M
JM
School of Paediatrics and Reproductive Health, Discipline of Obstetrics and Gynaecology, The University of Adelaide, Women's and Children's Hospital, 72 King William Road, Adelaide, South Australia, Australia, 5006.
Crowther
Caroline A
CA
D000020:Abortifacient Agents, Nonsteroidal; D000028:Abortion, Induced / Q000379:methods*; D000013:Congenital Abnormalities; D005260:Female; D005313:Fetal Death; D006801:Humans; D007751:Labor, Induced / Q000379:methods*; D016595:Misoprostol; D010120:Oxytocics; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third; D016032:Randomized Controlled Trials as Topic
D000020:Abortifacient Agents, Nonsteroidal; D010120:Oxytocics; D016595:Misoprostol
Aust N Z J Obstet Gynaecol. 1997 Aug;37(3):331-4
9325520
Int J Gynaecol Obstet. 2008 Jan;100(1):82-3
17888920
J Matern Fetal Med. 1998 May-Jun;7(3):115-9
9642607
Obstet Gynecol. 2003 Jun;101(6):1294-9
12798539
Int J Gynaecol Obstet. 2006 Mar;92(3):270-1
16430901
Eur J Contracept Reprod Health Care. 2009 Feb;14(1):55-60
19241302
Am J Obstet Gynecol. 1999 Nov;181(5 Pt 1):1057-61
10561618
Cochrane Database Syst Rev. 2001;(2):CD003092
11406071
Stat Med. 2002 Jun 15;21(11):1539-58
12111919
BJOG. 2005 Sep;112(9):1297-301
16101611
J Indian Med Assoc. 2006 Feb;104(2):81-2, 84
16856588
Cochrane Database Syst Rev. 2006 Apr 19;(2):CD001338
16625542
Trop Doct. 2001 Jul;31(3):157-61
11444340
Cochrane Database Syst Rev. 2011 Jan 19;(1):CD005216
21249669
Cochrane Database Syst Rev. 2003;(1):CD000941
12535398
Acta Obstet Gynecol Scand. 1998 Apr;77(4):429-32
9598952
BJOG. 2004 Feb;111(2):148-53
14723752
Arch Gynecol Obstet. 2005 Dec;273(3):157-60
16041629
Cochrane Database Syst Rev. 2001;(2):CD003098
11406075
J Matern Fetal Med. 1999 Mar-Apr;8(2):48-50
10090490
J Obstet Gynaecol. 2006 Aug;26(6):546-9
17000504
Am J Obstet Gynecol. 2004 Mar;190(3):755-62
15042010
Int J Gynaecol Obstet. 2005 Jun;89(3):276-7
15919397
Am J Obstet Gynecol. 2002 Mar;186(3):470-4
11904609
J Matern Fetal Neonatal Med. 2008 Nov;21(11):847-51
18979392
Cochrane Database Syst Rev. 2006 Jul 19;(3):CD002253
16855990
Cochrane Database Syst Rev. 2003;(4):CD003101
14583960
Rev Paul Med. 1988 Jul-Aug;106(4):205-8
3151520
Cochrane Database Syst Rev. 2001;(4):CD001233
11687101
Obstet Gynecol. 1999 Apr;93(4):571-5
10214835
Obstet Gynecol. 2003 Jan;101(1):70-3
12517648
Aust N Z J Obstet Gynaecol. 2001 Nov;41(4):407-10
11787914
Cochrane Database Syst Rev. 2000;(4):CD002864
11034778
J Med Assoc Thai. 2006 Oct;89 Suppl 4:S5-10
17726806
Int J Gynaecol Obstet. 2004 Nov;87(2):176-7
15491575
J Reprod Med. 2005 Mar;50(3):173-80
15841929
Am J Obstet Gynecol. 2002 Oct;187(4):853-7
12388963
J Obstet Gynaecol Res. 2001 Jun;27(3):125-8
11561827
N Engl J Med. 1994 Aug 4;331(5):290-3
8022438
J Obstet Gynaecol Can. 2005 Nov;27(11):1013-8
16529667
Am J Obstet Gynecol. 1996 Jul;175(1):173-7
8694046
Am J Obstet Gynecol. 2005 Oct;193(4):1410-4
16202734
Cochrane Database Syst Rev. 2001;(3):CD003246
11687060
Contraception. 2001 Feb;63(2):89-93
11292473
Eur J Obstet Gynecol Reprod Biol. 1996 Nov;69(2):97-102
8902440
Am J Obstet Gynecol. 2003 Sep;189(3):710-3
14526299
Fetal Diagn Ther. 2005 Nov-Dec;20(6):544-8
16260893
Int J Gynaecol Obstet. 2004 Jul;86(1):52-3
15207678
Afr Health Sci. 2001 Dec;1(2):55-9
12789117
Cochrane Database Syst Rev. 2007 Jul 18;(3):CD000494
17636640
J Obstet Gynaecol. 2003 Jul;23(4):407-11
12881083
J Gynecol Obstet Biol Reprod (Paris). 2001 Sep;30(5):439-43
11598557
Obstet Gynecol. 2004 Jul;104(1):138-45
15229013
Hum Reprod. 1995 Feb;10(2):475-8
7769082
East Afr Med J. 2004 Apr;81(4):179-82
15884282
Rev Paul Med. 1987 Nov-Dec;105(6):325-8
3144030
Obstet Gynecol. 1997 Dec;90(6):896-900
9397098
Pak J Biol Sci. 2008 Nov 1;11(21):2505-8
19205272